delandistrogene moxeparvovec Elevidys
Selected indexed studies
- Delandistrogene Moxeparvovec: First Approval. (Drugs, 2023) [PMID:37566211]
- AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. (Nat Med, 2025) [PMID:39385046]
- Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1-Year Interim Results from Study SRP-9001-103 (ENDEAVOR). (Ann Neurol, 2023) [PMID:37539981]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Delandistrogene Moxeparvovec: First Approval. (2023) pubmed
- AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. (2025) pubmed
- Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1-Year Interim Results from Study SRP-9001-103 (ENDEAVOR). (2023) pubmed
- Delandistrogene Moxeparvovec. (2012) pubmed
- Practical Considerations for Delandistrogene Moxeparvovec Gene Therapy in Patients With Duchenne Muscular Dystrophy. (2024) pubmed
- Delandistrogene moxeparvovec (Elevidys) for Duchenne muscular dystrophy. (2023) pubmed
- Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapy. (2025) pubmed
- Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial. (2024) pubmed
- Delandistrogene Moxeparvovec Gene Therapy in Individuals With Duchenne Muscular Dystrophy: Evidence in Focus: Report of the AAN Guidelines Subcommittee. (2025) pubmed
- Gene therapy for Duchenne muscular dystrophy. (2025) pubmed